Markus B H, Dickson E R, Grambsch P M, Fleming T R, Mazzaferro V, Klintmalm G B, Wiesner R H, Van Thiel D H, Starzl T E
Department of Surgery, University of Pittsburgh School of Medicine, (E.R.D., R.H.W.) and the Section of Biostatistics, PA 15213.
N Engl J Med. 1989 Jun 29;320(26):1709-13. doi: 10.1056/NEJM198906293202602.
No controlled trials have been performed to assess the efficacy of liver transplantation. Because of the marked improvement in survival after liver transplantation since 1981, random assignment of patients to a control group not undergoing transplantation is considered clinically inappropriate. To assess the efficacy of liver transplantation in patients with primary biliary cirrhosis, we compared survival in 161 patients with this diagnosis who had undergone a liver transplantation with survival in patients with the same diagnosis who had been treated conservatively. The comparison was performed with use of a recently developed statistical technique, the Mayo model. All patients had undergone liver transplantation between March 1980 and June 1987 and were followed for a median of 25 months. Three months after liver transplantation, the Kaplan-Meier survival probabilities in the recipients were substantially higher than the Mayo-model "simulated-control" survival probabilities (P less than 0.001). At two years, the Kaplan-Meier survival probability was 0.74, whereas the mean Mayo-model survival probability was 0.31. The patients who were at low risk according to the Mayo model had the best probability of survival after liver transplantation; however, patients at all risk levels who had undergone liver transplantation had higher probabilities of survival that those who had not. We conclude that liver transplantation is an efficacious treatment in patients with advanced primary biliary cirrhosis.
尚未进行对照试验来评估肝移植的疗效。由于自1981年以来肝移植术后生存率有显著提高,因此将患者随机分配至不接受移植的对照组在临床上被认为是不合适的。为了评估肝移植对原发性胆汁性肝硬化患者的疗效,我们比较了161例诊断为此病且接受了肝移植的患者的生存率与诊断相同但接受保守治疗的患者的生存率。使用一种最近开发的统计技术——梅奥模型进行了比较。所有患者均在1980年3月至1987年6月期间接受了肝移植,且中位随访时间为25个月。肝移植后三个月,受者的Kaplan-Meier生存概率显著高于梅奥模型的“模拟对照”生存概率(P<0.001)。在两年时,Kaplan-Meier生存概率为0.74,而梅奥模型的平均生存概率为0.31。根据梅奥模型处于低风险的患者肝移植后生存概率最佳;然而,所有风险水平接受肝移植的患者比未接受肝移植的患者有更高的生存概率。我们得出结论,肝移植是晚期原发性胆汁性肝硬化患者的一种有效治疗方法。